Literature DB >> 22593465

Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.

Hiromichi Matsuoka1, Chihiro Makimura, Atsuko Koyama, Masatomo Otsuka, Wataru Okamoto, Yasuhito Fujisaka, Hiroyasu Kaneda, Junji Tsurutani, Kazuhiko Nakagawa.   

Abstract

BACKGROUND: Neuropathic pain frequently occurs in cancer patients, but no drug therapy has been established for this type of disorder. The purpose of this study was to investigate the effect of duloxetine in cancer patients suffering from neuropathic pain. PATIENTS AND METHODS: The subjects of the study were 15 cancer patients with neuropathic pain who visited the Kinki University Faculty of Medicine Hospital and met the International Association for the Study of Pain diagnostic criteria for neuropathic pain. Duloxetine was administered to patients in whom pregabalin could not be administered. The influence of duloxetine was investigated retrospectively with the use of a numerical rating scale.
RESULTS: Pain was reduced in 7 out of the 15 patients. Sleepiness and the light-headed feeling were improved in four patients, in whom, however, the pain was not reduced. Thus, duloxetine was judged to be effective in 11 patients. The maintenance dose of duloxetine was 20-40 mg/day.
CONCLUSION: Duloxetine administration may be effective for neuropathic pain in cancer patients who cannot tolerate pregabalin administration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593465

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Psychopharmacology in psycho-oncology.

Authors:  Rosangela Caruso; Luigi Grassi; Maria Giulia Nanni; Michelle Riba
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

Review 2.  Treatment of Neuropathic Pain Directly Due to Cancer: An Update.

Authors:  Morena Shkodra; Augusto Caraceni
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

3.  Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?

Authors:  Shivani Shinde; Pamela Gordon; Prashant Sharma; James Gross; Mellar P Davis
Journal:  Support Care Cancer       Date:  2014-08-29       Impact factor: 3.603

Review 4.  Chemotherapy-induced neuropathies-a growing problem for patients and health care providers.

Authors:  Marta Banach; Judyta K Juranek; Aneta L Zygulska
Journal:  Brain Behav       Date:  2016-10-26       Impact factor: 2.708

Review 5.  Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.

Authors:  Ali H El-Far; Grazyna Sroga; Soad K Al Jaouni; Shaker A Mousa
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

6.  Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol.

Authors:  Hiromichi Matsuoka; Katherine Clark; Belinda Fazekas; Shunsuke Oyamada; Linda Brown; Hiroto Ishiki; Yoshinobu Matsuda; Hideaki Hasuo; Keisuke Ariyoshi; Jessica Lee; Brian Le; Peter Allcroft; Slavica Kochovska; Noriko Fujiwara; Tempei Miyaji; Melanie Lovell; Meera Agar; Takuhiro Yamaguchi; Eriko Satomi; Satoru Iwase; Jane Phillips; Atsuko Koyama; David C Currow
Journal:  BMJ Open       Date:  2022-02-07       Impact factor: 2.692

Review 7.  Review of a study of duloxetine for painful chemotherapy-induced peripheral neuropathy.

Authors:  Rita Wickham
Journal:  J Adv Pract Oncol       Date:  2013-09

8.  A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin.

Authors:  Hiroshi Kato; Masayuki Miyazaki; Mio Takeuchi; Hiroaki Tsukuura; Mihoko Sugishita; Yukihiro Noda; Kiyofumi Yamada
Journal:  J Pharm Health Care Sci       Date:  2015-07-16

9.  Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.

Authors:  Hiromichi Matsuoka; Hiroto Ishiki; Satoru Iwase; Atsuko Koyama; Takashi Kawaguchi; Yoshiyuki Kizawa; Tatsuya Morita; Yoshinobu Matsuda; Tempei Miyaji; Keisuke Ariyoshi; Takuhiro Yamaguchi
Journal:  BMJ Open       Date:  2017-08-28       Impact factor: 2.692

10.  Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis.

Authors:  Soo Youn Song; Young Bok Ko; Hyeun Kim; Geon Woo Lee; Jung Bo Yang; Ha Kyun Chang; Sang Mi Kwak; Jaeyun Jung; Siyeo Lee; Sun Yeul Lee; Heon Jong Yoo
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.